1800 244 735

Helpline (02) 9874 9777

HD Therapeutics Conference 2012 Updates: Day 2

Our second daily report from the annual Huntington’s Disease Therapeutics Conference in Palm Springs, California. The second day’s sessions focused on gene silencing. You can tweet @HDBuzzFeed or email palmsprings@hdbuzz.net with your questions, comments and queries.

Wednesday, February 29, 2012

9:03 – HD Therapeutics Conference Update: This morning is focused on gene silencing – a very exciting potential therapy. Stand by!

9:35 – Beverly Davidson (University of Iowa): silencing the mutant HD gene in mice has clear benefits, but we need to consider any unintended toxic effects

9:45 – Davidson is behind one of three recent papers showing huntingtin gene silencing safe in primates – a key step to human trials

9:49 – Davidson’s team is now working on new gene silencing drugs that silence the mutant copy of the gene more than the ‘healthy’ copy.

9:50 – Targeting the mutant gene selectively might be safer but is more challenging. Both approaches are being worked on.

10:06 – Frank Bennett (Isis Pharmaceuticals) uses slightly different DNA-like molecules called ASOs to silence the Huntingtin gene

10:07 – Bennett: Huntingtin seems to be relatively easy to silence compared to other genes – lucky break!

10:00 – Bennett’s ASO drugs are absorbed into cells better then RNAi drugs. Might make it easier to get to patients – no brain surgery?

10:13 – Bennett’s company Isis pharmaceuticals is experienced in gene silencing – 2,000+ patients with other diseases have received their drugs

10:17 – Bennett: when tested in 2 different HD mouse models, ASO gene silencing drugs produced improvements in coordination and cognition

10:19 – Bennett: infusion of ASO into the fluid at the base of the spine in primates is enough to get the drug to large areas of the brain

10:22 – Bennett: even one-off injections of the gene silencing ASO may be enough to treat the brain. But deep brain regions harder to reach

10:25 – Bennett: many people have small spelling differences, apart from the expanded CAG, between the 2 copies of Huntingtin gene. These differences can be targeted, to design drugs that silence only the mutant gene.

11:04 – Steve Zhang (Sangamo BioSciences): ‘zinc finger proteins’ can bind to specific DNA sequences, raising the possibility of ‘editing’ our genes

11:07 – For anyone wanting more detail, video of the talks will be available online soon, and we’re writing a summary article too

11:00 – Zhang: other uses of zinc finger proteins include designing stem cells to study generic diseases in human cells

11:18 – Zhang’s company Sangamo has successfully treated hemophilia in a mouse model using ‘genome editing’

11:19 – Zhang: Zinc fingers can also be used to switch genes on and off, another possible approach to gene silencing

11:20 – Zhang: we could also try to switch on helpful genes, so that the brain produces more protective chemicals

11:25 – Zhang: zinc finger drug that makes the brain produce the protective chemical GDNF is about to start a trial in Parkinson’s disease

11:26 – Sangamo is now involved in Huntington’s disease research.

11:29 – Zhang: Sangamo’s current strategy is to try to reduce Huntingtin production with a tailor-made zinc finger drug

11:36 – Zhang: they’re also working on a zinc finger silencing drug that only works on huntingtin genes with expanded CAG repeats

11:53 – Bill Kaemmerer (Medtronic): To make new silencing trials happen we need ‘biomarkers’- tests of safety & measurements to tell us if it’s working

12:02 – Kaemmerer: A combination of MR imaging, CSF chemicals and clinical measures will be used for early RNAi gene silencing trials

12:07 – Kaemmerer is part of the team behind another recent primate safety trial of huntingtin gene silencing

12:37 – Neil Aronin (University of Massachusetts School of Medicine) and his team are trying to understand how one gene silencing approach, RNAi, works in great detail to design good drugs

12:46 – Aronin and his team are are using sheep to practice the neurosurgical techniques needed for gene silencing trials in humans

Sunset conclusions

Several different strategies are being developed in parallel to ‘silence’ the huntingtin gene that’s the ultimate cause of all problems in HD. There are a few wrinkles to iron out, but basically so far each approach has cleared every hurdle it’s encountered. Several clinical trials involving HD patients are being planned, all aiming for a rapid start – within months rather than years. The stakes are high, but it’s a genuinely exciting time.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Meeting 2021

Published date: 28 October, 2021

Last month, the Huntington’s disease (HD) research community, patients and other stakeholders met online at the European Huntington’s disease network (EHDN) conference. Despite the ongoing global pandemic, there is a tremendous amount of work underway in labs and clinics around the world as researchers continue to better understand HD and how we might best treat ... Read more

Real talk: Q&A with Roche about GENERATION-HD1

Published date: 28 September, 2021

At the end of day 1 of the European Huntington’s Disease Network (EHDN) conference, the HDBuzz team (minus one) sat down for a zoom chat with the team at Roche to have a frank, candid discussion about the recent halting of GENERATION-HD1, the Phase 3 clinical trial that was testing the ability of the antisense ... Read more

Another tool in the box: Creation of a molecular “dimmer switch” advances gene editing

Published date: 30 August, 2021

A team of scientists recently created an innovative genetic system where a drug taken by mouth could be used to control the action of a gene editor, like those used in CRISPR systems. This has useful applications for research studies in cells and animals, and perhaps most importantly, could lead to improvements in the safety ... Read more

Unpacking recent gene therapy press

Published date: 16 August, 2021

A recent announcement from Voyager Therapeutics outlined a shift in the company’s strategy towards an exciting new technology for gene therapy delivery. Unfortunately this also means that in the short term, they have dropped previous plans to test an HD gene therapy in people with HD. While this news is disappointing, the decision to embrace ... Read more

Does blood hold the key to testing treatments earlier in HD patients?

Published date: 4 August, 2021

Researchers at Johns Hopkins led by Wenzhen Duan have developed a non-invasive way to track progression of Huntington’s disease (HD) which could be used before patients even start showing symptoms. Using a type of brain scan called an MRI, the researchers have shown that in mouse models of HD they can accurately measure the amount ... Read more

A first for CRISPR gene editing could have wider applications for human disease

Published date: 21 July, 2021

A recent clinical trial successfully tested the safety of CRISPR gene editing to reduce the amount of a toxic protein in patients with Familial Transthyretic (TTR) Amyloidosis. Although this study is unrelated to Huntington’s disease, it’s a first for gene editing, and the results could have implications for HD and other brain disorders. CRISPR-Cas9 Clustered ... Read more